CL2019003459A1 - Métodos de cultivo celular. - Google Patents

Métodos de cultivo celular.

Info

Publication number
CL2019003459A1
CL2019003459A1 CL2019003459A CL2019003459A CL2019003459A1 CL 2019003459 A1 CL2019003459 A1 CL 2019003459A1 CL 2019003459 A CL2019003459 A CL 2019003459A CL 2019003459 A CL2019003459 A CL 2019003459A CL 2019003459 A1 CL2019003459 A1 CL 2019003459A1
Authority
CL
Chile
Prior art keywords
recombinant protein
weight
cell culture
total
produced
Prior art date
Application number
CL2019003459A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Jeffrey Yates
Yahia Bassem Ben
Laetitia Malphettes
Nadine Kochanowski
Gill Renner
Sandrine Durran
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2019003459A1 publication Critical patent/CL2019003459A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00Cells for large scale production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2019003459A 2017-05-31 2019-11-26 Métodos de cultivo celular. CL2019003459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods

Publications (1)

Publication Number Publication Date
CL2019003459A1 true CL2019003459A1 (es) 2020-04-24

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003459A CL2019003459A1 (es) 2017-05-31 2019-11-26 Métodos de cultivo celular.

Country Status (21)

Country Link
US (3) US12077796B2 (enExample)
EP (2) EP4397682A3 (enExample)
JP (3) JP7460370B2 (enExample)
KR (3) KR20240096888A (enExample)
CN (2) CN119326882A (enExample)
AU (2) AU2018276376C1 (enExample)
BR (1) BR112019024390A2 (enExample)
CA (1) CA3065661A1 (enExample)
CL (1) CL2019003459A1 (enExample)
CO (1) CO2019012871A2 (enExample)
EA (1) EA201992828A1 (enExample)
ES (1) ES2978394T3 (enExample)
GB (1) GB201708655D0 (enExample)
HR (1) HRP20240585T1 (enExample)
HU (1) HUE066922T2 (enExample)
IL (2) IL317828A (enExample)
MX (1) MX2019014140A (enExample)
MY (1) MY193535A (enExample)
PL (1) PL3630946T3 (enExample)
RU (2) RU2758674C2 (enExample)
WO (1) WO2018219968A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP2218775B1 (en) 1996-08-30 2015-01-28 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
EP1441589B1 (en) 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
CN104152395B (zh) * 2006-11-08 2020-03-10 惠氏公司 合理设计的细胞培养基
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CA2797140C (en) 2010-04-26 2018-01-23 Novartis Ag Improved cell culture medium
CN102858954A (zh) 2010-04-26 2013-01-02 诺瓦提斯公司 改进的细胞培养方法
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なIgG4に基づく結合剤の製剤
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック, インコーポレイテッド 細胞培養培地及び抗体を産生する方法
KR102434588B1 (ko) 2014-06-18 2022-08-22 메디뮨 엘엘씨 N-아세틸시스테인을 포함하는 세포 배양 방법 및 배지
KR20170100074A (ko) 2014-12-29 2017-09-04 완롭 위롯페이싯 상승된 전압 및 향상된 장착 방식을 구비한 엔진 연소시스템의 산소효율 증진장치
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
ES2967868T3 (es) 2016-04-28 2024-05-06 Merck Patent Gmbh Método para reducir el nivel de trisulfuro en proteínas
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
GB201708655D0 (en) 2017-07-12
AU2024259881A1 (en) 2024-11-28
RU2021128024A (ru) 2021-12-08
CN119326882A (zh) 2025-01-21
US20250066832A1 (en) 2025-02-27
EP3630946C0 (en) 2024-03-27
AU2018276376B2 (en) 2024-08-15
AU2018276376A1 (en) 2019-12-12
AU2024259881B2 (en) 2025-02-13
CN110741077A (zh) 2020-01-31
US20200239923A1 (en) 2020-07-30
JP2022153421A (ja) 2022-10-12
KR20200012972A (ko) 2020-02-05
BR112019024390A2 (pt) 2020-07-14
CO2019012871A2 (es) 2020-01-17
AU2018276376C1 (en) 2025-01-30
MY193535A (en) 2022-10-18
CA3065661A1 (en) 2018-12-06
EA201992828A1 (ru) 2020-04-21
IL317828A (en) 2025-02-01
HUE066922T2 (hu) 2024-09-28
IL270880A (en) 2020-01-30
JP2021185185A (ja) 2021-12-09
JP2020521490A (ja) 2020-07-27
WO2018219968A1 (en) 2018-12-06
EP4397682A2 (en) 2024-07-10
MX2019014140A (es) 2020-02-07
KR20250156183A (ko) 2025-10-31
EP3630946A1 (en) 2020-04-08
PL3630946T3 (pl) 2024-07-01
JP7406593B2 (ja) 2023-12-27
US12077796B2 (en) 2024-09-03
RU2019143742A3 (enExample) 2021-06-30
HRP20240585T1 (hr) 2024-07-19
IL270880B1 (en) 2025-01-01
ES2978394T3 (es) 2024-09-11
CN110741077B (zh) 2024-10-11
IL270880B2 (en) 2025-05-01
JP7560420B2 (ja) 2024-10-02
EP3630946B1 (en) 2024-03-27
US20250051824A1 (en) 2025-02-13
JP7460370B2 (ja) 2024-04-02
KR20240096888A (ko) 2024-06-26
RU2758674C2 (ru) 2021-11-01
RU2019143742A (ru) 2021-06-30
EP4397682A3 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
MX2025003310A (es) Integracion dirigida de acidos nucleicos
EA201791443A1 (ru) Естественные киллерные клетки и их применения
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
EA201692498A1 (ru) Способы сбора культур клеток млекопитающих
CL2019003459A1 (es) Métodos de cultivo celular.
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
MX375911B (es) Constructos de anticuerpo multiespecifico.
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
CO2018001420A2 (es) Biomasa rica en proteína de traustoquitridios, método de cultivo y utilización
EA201270304A1 (ru) Способы получения шелковой пасты
UY36475A (es) Composiciones y metodos para el uso de insecticida con bacillus sp d747
EA202190326A3 (ru) Не содержащая сыворотки среда для культивирования клеток
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
EA201791416A1 (ru) Популяции клеток rpe и способы их получения
BR112016024911A2 (pt) composições de proteínas solúveis e métodos de sua produçâo
MX2021000421A (es) Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
BR112018012070A2 (pt) método para a produção de tecidos/ órgãos utilizando células sanguíneas
MX387420B (es) Producción de virus en cultivos celulares.
AR090340A1 (es) Operaciones de cosecha mejoradas para proteinas recombinadas
EA201691953A1 (ru) Белки тонопласта, функционирующие как протон/сахар-антипортеры, и их использование для повышения концентрации сахарозы в запасающем сахарозу органе растений
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
EA202090133A1 (ru) Способ получения трансплантируемой хрящевой ткани